Reducing vaccination disparities during a national emergency response: the U.S. Mpox Vaccine Equity Pilot Program
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

Reducing vaccination disparities during a national emergency response: the U.S. Mpox Vaccine Equity Pilot Program



Public Access Version Available on: January 01, 2025, 12:00 AM
Please check back on the date listed above.
English

Details:

  • Alternative Title:
    J Public Health Manag Pract
  • Personal Author:
  • Corporate Authors:
  • Description:
    Context:

    In response to the first reported mpox cases in May 2022, the United States Government (USG) implemented plans to bring testing, treatment, and vaccines to communities disproportionately affected by mpox—including the population of men who have sex with men and Black/African American and Hispanic/Latino men, two sub-populations experiencing vaccination disparities. We describe the development and implementation of the U.S. Mpox Vaccine Equity Pilot Program (MVEPP), characteristics of completed vaccination projects, and challenges that occurred. We also discuss opportunities for reducing vaccination disparities in future outbreaks.

    Program:

    To address reported vaccination disparities, the USG launched MVEPP in two phases. Phase one centered around public events attended by large numbers of gay, bisexual, and other men who have sex with men (MSM), such as pride festivals. Phase two asked health departments to propose mpox vaccination projects specifically aimed at reducing or eliminating racial/ethnic and other demographic disparities in mpox vaccination.

    Implementation:

    MVEPP received 35 vaccination project proposals. We analyzed data from 22 completed projects which resulted in 25,675 doses of JYNNEOS administered. We note three innovative strategies that were implemented in several projects: direct collaboration with organizations providing services to MSM and transgender women; implementation of MVEPP projects in unique non-clinical community settings and at venues frequented by MSM and transgender women; and offering an array of services as part of mpox vaccination projects, rather than offering only mpox vaccination.

    Evaluation:

    MVEPP highlighted the importance of recognizing and working to eliminate racial/ethnic and other disparities in access to medical countermeasures during a public health emergency. Jurisdictions developed and implemented innovative strategies to bring mpox vaccination and related services to communities disproportionately affected by mpox—including MSM and the subpopulations of Black/African American and Hispanic/Latino MSM. Lessons learned from MVEPP may inform efforts to reduce disparities during future public health responses.

  • Keywords:
  • Source:
  • Pubmed ID:
    37678261
  • Pubmed Central ID:
    PMC10843777
  • Document Type:
  • Funding:
  • Volume:
    30
  • Issue:
    1
  • Collection(s):
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov